Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: An economic evaluation of increasing the frequency of ivermectin treatment in Africa

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages 923-932

  Turner, Hugo C ^a   Walker, Martin ^a   Churcher, Thomas S ^a   Osei Atweneboana, Mike Y ^b   Biritwum, Nana Kwadwo ^c   Hopkins, Adrian ^d   Prichard, Roger K ^e   Basáñez, María Gloria ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CSIR WATER RESEARCH INSTITUTE   (Ghana)

^c GHANA HEALTH SERVICE   (Ghana)

^d Mectizan Donation Program   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Cost effectiveness; Economic evaluation; Ivermectin; Onchocerciasis; Treatment frequency

Indexed keywords

IVERMECTIN; ANTHELMINTIC AGENT;

AFRICA; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ENDEMIC DISEASE; FEMALE; HUMAN; MEDICATION COMPLIANCE; NONHUMAN; ONCHOCERCIASIS; PATIENT COMPLIANCE; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT INTERRUPTION; DISEASE ERADICATION; ECONOMICS; HEALTH CARE COST; NEGLECTED DISEASES;

AFRICA; ANTHELMINTICS; DISEASE ERADICATION; HEALTH CARE COSTS; HUMANS; IVERMECTIN; NEGLECTED DISEASES; ONCHOCERCIASIS;

EID: 84964313551     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu467     Document Type: Article

References (42)

1. Duke BOL. Human onchocerciasis - an overview of the disease. Acta Leiden 1990; 59:9-24.
2. Brattig NW. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004; 6:113-28.
3. Little MP, Breitling LP, Basáñez MG, Alley ES, Boatin BA. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet 2004; 363:1514-21.
4. Walker M, Little MP, Wagner KS, Soumbey-Alley EW, Boatin BA, Basáñez MG. Density-dependent mortality of the human host in onchocerciasis: relationships between microfilarial load and excess mortality. PLoS Negl Trop Dis 2012; 6:e1578.
5. Meredith SEO, Dull HB. Onchocerciasis: the first decade of Mectizan treatment. Parasitol Today 1998; 14:472-4.
6. World Bank. Pushing back neglected tropical diseases in Africa, 2012. Available at: http://www.worldbank.org/en/news/feature/2012/11/17/ pushing-back-neglected-tropical-diseases-in-africa. Accessed 2 July 2014.
7. London Declaration on Neglected Tropical Diseases. Ending the neglect and reaching 2020 goals, 2012. Available at: http://unitingtocombatntds. org/downloads/press/ntd-event-london-declaration-on-ntds.pdf. Accessed 6 November 2013.
8. World Health Organization. World Health Organization's 2020 roadmap on NTDs, 2012. Available at: http://www.who.int/neglected- diseases/NTD-RoadMap-2012-Fullversion.pdf. Accessed 6 November 2013.
9. Ndyomugyenyi R, Lakwo T, Habomugisha P, Male B. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward. Ann Trop Med Parasitol 2007; 101:323-33.
10. Gustavsen K, Hopkins A, Sauerbrey M. Onchocerciasis in the Americas: from arrival to (near) elimination. Parasit Vectors 2011; 4:205.
11. Burki T. River blindness elimination in Columbia. Lancet Infect Dis 2013; 13:922-3.
12. West S, Munoz B, Sommer A. River blindness eliminated in Colombia. Ophthalmic Epidemiol 2013; 20:258-9.
13. World Health Organization/African Programme for Onchocerciasis Control. Onchocerciasis control in special intervention zones including Sierra Leone in the OCP area. Joint Programme Committee Report. September 2002. Ouagadougou, Burkina Faso:World Health Organization/ African Programme for Onchocerciasis Control, 2002.
14. Filipe JAN, Boussinesq M, Renz A, et al. Human infection patterns and heterogeneous exposure in river blindness. Proc Natl Acad Sci U S A 2005; 102:15265-70.
15. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG. Uncertainty surrounding projections of the long-term impact of ivermectin treatment for human onchocerciasis. PLoS Negl Trop Dis 2013; 7:e2169.
16. Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:310-22.
17. Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy. Acta Trop 2011; 120(suppl 1): S100-8.
18. Turner HC,Walker M, Churcher TS, Basáñez MG. Modelling the impact of ivermectin on river blindness and its burden of morbidity and mortality in African savannah: EpiOncho projections. Parasit Vectors 2014; 7:241.
19. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue Duke BOL. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet 2002; 360:203-10.
20. Winnen M, Plaisier AP, Alley ES, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 2002; 80:384-91.
21. Diawara L, Traoré MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009; 3: e497.
22. Traore MO, Sarr MD, Badji A, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis 2012; 6:e1825.
23. African Programme for Onchocerciasis Control. Conceptual and Operational Framework of Onchocerciasis Elimination with Ivermectin Treatment, 2010. Available at: http://http://www.who.int/apoc/oncho- elimination-report-english.pdf. Accessed 2 July 2014.
24. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford, UK: Oxford Science Publications, 1992.
25. Turner HC, Osei-Atweneboana MY,Walker M, et al. The cost of annual versus biannual community-directed treatment with ivermectin: Ghana as a case study. PLoS Negl Trop Dis 2013; 7:e2452.
26. Coffeng LE, Stolk WA, Zouré HGM, et al. African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost. PLoS Negl Trop Dis 2013; 7:e2032.
27. Prost A, Hervouet JP, Thylefors B. Les niveaux d'endmicité dans l'onchocercose. Bull World Health Organ 1979; 57:655-62.
28. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003. Available at: http://www.who.int/choice/publications/p-2003-general ised-cea.pdf. Accessed 6 November 2013.
29. World Bank. World development report 1993: investing in health. New York: Oxford University Press, 1993. Available at: https:// openknowledge.worldbank.org/handle/10986/5976. Accessed 2 July 2014.
30. Benton B. Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann Trop Med Parasitol 1998; 92(suppl 1):S33-S9.
31. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM. Tropical diseases targeted for elimination: chagas disease, lymphatic dilariasis, onchocerciasis, and leprosy. In: Jamison DT, Breman JG, Measham AR. Disease control priorities in developing countries. New York: Oxford University Press, 2006:433-49. Available at: http://www.ncbi.nlm.nih. gov/books/NBK11745/pdf/ch22.pdf. Accessed 6 November 2013.
32. Higazi TB, Zarroug IM, Mohamed HA, et al. Interruption of Onchocerca volvulus transmission in the Abu Hamed focus, Sudan. Am J Trop Med Hyg 2013; 89:51-7.
33. Katabarwa MN,Walsh F, Habomugisha P, et al. Transmission of onchocerciasis inWadelai focus of northwestern Uganda has been interrupted and the disease eliminated. J Parasitol Res 2012; 2012:748540.
34. World Health Organization. Criteria for certification of interruption of transmission/elimination of human onchocerciasis. Report of a meeting held in Geneva, 28-29 September 2000. Geneva: World Health Organization, 2001; WHO/CDS/CPE/CEE/2001.18a. Available at: http://www. oepa.net/Documentos/CriteriosCertificacionOMS/WHO-CDS-CPE- CEE-2001.18a.pdf. Accessed 1st April 2014.
35. World Health Organization. Progress towards eliminating onchocerciasis in the WHO region of the Americas: verification by WHO of elimination of transmission in Colombia. Wkly Epidemiol Rec 2013; 88:381-5. Available at: http://www.who.int/wer/2013/wer8836.pdf. Accessed 1 April 2014.
36. Oguttu D, Byamukama E, Katholi CR, et al. Serosurveillance to monitor onchocerciasis elimination: the Ugandan experience. Am J Trop Med Hyg 2014; 90:339-45.
37. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010; 376:1175-85.
38. StolkWA, ten Bosch QA, de Vlas SJ, Fischer PU,Weil GJ, Goldman AS. Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl Trop Dis 2013; 7:e1984.
39. Bradley JE, Whitworth J, Basáñez MG. Chapter 39: Onchocerciasis. In: Wakelin D, Cox F, Despommier D, Gillespie S, eds. Topley andWilson's microbiology and microbial infections. 10th edn (Parasitology Volume). London: Edward Arnold Publishers Ltd, 2005:781-801.
40. Dadzie KY, Remme JHF, Rolland A, Thylefors B. Ocular onchocerciasis and intensity of infection in the community. II. West African rainforest foci of the vector Simulium yahense. Trop Med Parasitol 1989; 40: 348-54.
41. Osei-Atweneboana MY, Eng JKL, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007; 369:2021-9.
42. Churcher TS, Pion SDS, Osei-Atweneboana MY, et al. Identifying suboptimal responses to ivermectin in the treatment of river blindness. Proc Natl Acad Sci U S A 2009; 106:16716-21.